Methods for generating engineered human primary blood dendritic cell lines
AssigneeUniversity of Maryland, Baltimore
InventorHua Cheng
Life of this patent
Estimating the term…
Abstract
Provided are engineered primary blood and monocyte-derived dendritic cells, wherein the dendritic cell expresses a functional Tax protein from a T cell leukemia virus, and methods of making and using the same.
Claims15
An engineered primary blood dendritic cell, wherein the dendritic cell is genetically engineered to express a functional Tax protein from a T cell leukemia virus, wherein the dendritic cell is CD205+ and CD11c+, wherein the dendritic cell presents one or more antigens or antigenic fragments or variants thereof, wherein the one or more antigens or antigenic fragments or variants thereof is from a cancer cell or a pathogen, wherein the pathogen is selected from bacteria, fungi, parasite or virus, wherein the virus is not a T cell leukemia virus, wherein the Tax protein is from HTLV-2.
An engineered primary blood dendritic cell, wherein the dendritic cell is genetically engineered to express a functional Tax protein from a T cell leukemia virus, wherein the dendritic cell is CD205+ and CD11c+, wherein the dendritic cell presents one or more antigens or antigenic fragments or variants thereof, wherein the Tax protein is from HTLV-2.
An engineered primary blood dendritic cell, wherein the dendritic cell is genetically engineered to express a functional Tax protein from a T cell leukemia virus, wherein the dendritic cell is CD205+ and CD11c+, wherein the dendritic cell presents one or more antigens or antigenic fragments or variants thereof, wherein the one or more antigens or antigenic fragments or variants thereof is human telomerase reverse transcriptase or an antigenic fragment or variant thereof.
Dependencies are inferred from the claim text.